obstructive sleep apnea

Obstructive sleep apnea (OSA) is a prevalent sleep-related breathing disorder characterized by the repeated, involuntary collapse or narrowing of the pharyngeal airway during sleep. This mechanical obstruction results in partial (hypopnea) or complete (apnea) cessation of airflow, which triggers a cascade of physiological stressors, including oxygen desaturation, sleep fragmentation due to frequent micro-arousals, and significant sympathetic nervous system activation. Unlike central sleep apnea, which stems from a failure of neurological signaling, OSA is primarily an anatomical and structural issue often exacerbated by soft tissue deposition, such as upper airway fat, or anatomical abnormalities like tonsillar hypertrophy.

The clinical presentation of OSA frequently includes habitual, loud snoring—a result of throat tissue vibration—as well as choking or gasping during sleep, morning grogginess, and chronic daytime sleepiness. Diagnosis is confirmed through polysomnography, the gold standard for sleep studies, which typically identifies the condition when an individual experiences at least five apneas or hypopneas per hour of sleep diagnosis criteria. Despite its significant health implications, OSA remains substantially underdiagnosed, with estimates suggesting that 80–90% of adult cases go unrecognized underdiagnosis rate.

Epidemiologically, OSA affects a broad spectrum of the population, with prevalence estimates ranging from 2% to 20% among adults, depending on the diagnostic criteria and demographic factors applied 10-20% adult cases diagnosed. The condition is strongly associated with obesity—particularly central adiposity and increased neck circumference—as well as male gender, advancing age, and familial or genetic predispositions obesity key OSA determinant. In children, the prevalence is approximately 2%, often driven by enlarged tonsils or adenoids, though pediatric diagnostic criteria differ from those used for adults child prevalence 2%.

The significance of OSA lies in its role as a multisystem health risk. The intermittent hypoxia and sympathetic surges associated with the disorder lead to acute blood pressure spikes of 30 mm Hg or more during the night nightly BP surges. Over time, this contributes to a dose-response relationship with systemic hypertension, as well as an elevated risk for cardiovascular events, including stroke, myocardial infarction, and arrhythmias OSA-hypertension dose-response. Furthermore, OSA is linked to metabolic dysfunction, including insulin resistance, glucose intolerance, and Type 2 diabetes, and has been associated with neurodegenerative disorders, cognitive deficits, and certain cancer risks CV disease implications.

Management of OSA prioritizes Continuous Positive Airway Pressure (CPAP) therapy, which is considered the most effective intervention for reducing daytime sleepiness, lowering blood pressure, and improving glycemic control in patients with comorbid diabetes CPAP most effective. Other therapeutic approaches include weight loss, which can significantly reduce the severity of the obstruction, as well as dental appliances and surgical interventions like uvulopalatopharyngoplasty, though these are generally considered less effective than CPAP. For pediatric patients, adenotonsillectomy is frequently the first-line treatment. By addressing the airway obstruction, these interventions mitigate the systemic inflammatory and sympathetic consequences of the disorder, thereby reducing long-term mortality and morbidity risks.